High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials

Abstract The Antibody Mediated Prevention (AMP) trials (NCT02716675 and NCT02568215) demonstrated that passive administration of the broadly neutralizing monoclonal antibody VRC01 could prevent some HIV-1 acquisition events. Here, we use mathematical modeling in a post hoc analysis to demonstrate th...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Daniel B. Reeves, Bryan T. Mayer, Allan C. deCamp, Yunda Huang, Bo Zhang, Lindsay N. Carpp, Craig A. Magaret, Michal Juraska, Peter B. Gilbert, David C. Montefiori, Katharine J. Bar, E. Fabian Cardozo-Ojeda, Joshua T. Schiffer, Raabya Rossenkhan, Paul Edlefsen, Lynn Morris, Nonhlanhla N. Mkhize, Carolyn Williamson, James I. Mullins, Kelly E. Seaton, Georgia D. Tomaras, Philip Andrew, Nyaradzo Mgodi, Julie E. Ledgerwood, Myron S. Cohen, Lawrence Corey, Logashvari Naidoo, Catherine Orrell, Paul A. Goepfert, Martin Casapia, Magdalena E. Sobieszczyk, Shelly T. Karuna, Srilatha Edupuganti
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Nature Portfolio 2023-12-01
Saila:	Nature Communications
Sarrera elektronikoa:	https://doi.org/10.1038/s41467-023-43384-y
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!